Inflammatory bowel disease events after exposure to interleukin 17 inhibitors secukinumab and ixekizumab: Postmarketing analysis from the RADAR (“Research on Adverse Drug events And Reports”) program

Kelsey A. Orrell, Morgan Murphrey, Ryan C. Kelm, Harrison H. Lee, David R. Pease, Anne E. Laumann, Dennis P. West, Beatrice Nardone*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

33 Scopus citations

Fingerprint

Dive into the research topics of 'Inflammatory bowel disease events after exposure to interleukin 17 inhibitors secukinumab and ixekizumab: Postmarketing analysis from the RADAR (“Research on Adverse Drug events And Reports”) program'. Together they form a unique fingerprint.